JPH11506614A - 組換えアライグマポックスウイルス、およびネコ免疫不全症ウイルス感染症に対する有効なワクチンとしてのその使用 - Google Patents
組換えアライグマポックスウイルス、およびネコ免疫不全症ウイルス感染症に対する有効なワクチンとしてのその使用Info
- Publication number
- JPH11506614A JPH11506614A JP9501086A JP50108697A JPH11506614A JP H11506614 A JPH11506614 A JP H11506614A JP 9501086 A JP9501086 A JP 9501086A JP 50108697 A JP50108697 A JP 50108697A JP H11506614 A JPH11506614 A JP H11506614A
- Authority
- JP
- Japan
- Prior art keywords
- fiv
- virus
- feline
- vaccine
- gag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000713800 Feline immunodeficiency virus Species 0.000 title claims abstract description 125
- 229960005486 vaccine Drugs 0.000 title claims abstract description 44
- 241000700638 Raccoonpox virus Species 0.000 title claims abstract description 42
- 230000009385 viral infection Effects 0.000 title description 5
- 241000282326 Felis catus Species 0.000 claims abstract description 58
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 239000012634 fragment Substances 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 19
- 230000002163 immunogen Effects 0.000 claims abstract description 18
- 239000002671 adjuvant Substances 0.000 claims abstract description 16
- 101710091045 Envelope protein Proteins 0.000 claims abstract description 12
- 101710188315 Protein X Proteins 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 101710177291 Gag polyprotein Proteins 0.000 claims abstract description 11
- 101710125418 Major capsid protein Proteins 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 7
- 239000003085 diluting agent Substances 0.000 claims abstract description 5
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- 102100021696 Syncytin-1 Human genes 0.000 claims abstract 10
- 241000700605 Viruses Species 0.000 claims description 56
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 241000282324 Felis Species 0.000 claims description 10
- 241001647378 Chlamydia psittaci Species 0.000 claims description 3
- 241000711475 Feline infectious peritonitis virus Species 0.000 claims description 3
- 241000701915 Feline panleukopenia virus Species 0.000 claims description 3
- 241000726306 Irus Species 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 241001480037 Microsporum Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000003053 immunization Effects 0.000 claims 3
- 238000002649 immunization Methods 0.000 claims 3
- 241000711573 Coronaviridae Species 0.000 claims 2
- 241000714201 Feline calicivirus Species 0.000 claims 2
- 241000714165 Feline leukemia virus Species 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 210000004885 white matter Anatomy 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 1
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 241000282330 Procyon lotor Species 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 241000732549 Sphaerius Species 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
- 229920001184 polypeptide Polymers 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 44
- 108020004414 DNA Proteins 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 23
- 208000015181 infectious disease Diseases 0.000 description 22
- 238000002255 vaccination Methods 0.000 description 20
- 238000012546 transfer Methods 0.000 description 19
- 108700004025 env Genes Proteins 0.000 description 18
- 239000013615 primer Substances 0.000 description 17
- 210000003501 vero cell Anatomy 0.000 description 14
- 239000013592 cell lysate Substances 0.000 description 13
- 238000010367 cloning Methods 0.000 description 12
- 108700004026 gag Genes Proteins 0.000 description 12
- 101150030339 env gene Proteins 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 101150098622 gag gene Proteins 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000007758 minimum essential medium Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 206010058874 Viraemia Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 108091005703 transmembrane proteins Proteins 0.000 description 7
- 102000035160 transmembrane proteins Human genes 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 229920001400 block copolymer Polymers 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108091033380 Coding strand Proteins 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102100034353 Integrase Human genes 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- -1 Pyrene-polyoxyethylene Chemical group 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 241000223997 Toxoplasma gondii Species 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 108010078428 env Gene Products Proteins 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000000207 lymphocyte subset Anatomy 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 235000020030 perry Nutrition 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 208000010753 nasal discharge Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 210000000059 tachyzoite Anatomy 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229950004398 broxuridine Drugs 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 101150033242 lpxC gene Proteins 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 101150016099 omcA gene Proteins 0.000 description 2
- 244000039328 opportunistic pathogen Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102400000125 Cyclin-dependent kinase 5 activator 1, p25 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710142246 External core antigen Proteins 0.000 description 1
- 208000004729 Feline Leukemia Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 101710183568 Serine/threonine-protein kinase PknK Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- CECABOMBVQNBEC-UHFFFAOYSA-K aluminium iodide Chemical compound I[Al](I)I CECABOMBVQNBEC-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010015915 eye discharge Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 208000010949 lymph node disease Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000012211 viral plaque assay Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/819—Viral vaccine for feline species, e.g. cats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ネコ免疫不全症ウイルス(FIV)のエンベロープ蛋白質またはそれからの 免疫原性フラグメントをコードするDNA配列を含む少なくとも1個の内部遺伝 子(internal gene)を有する組換えアライグマポックスウイルス。 2.該内部遺伝子が、図3記載のアミノ酸配列を有するFIVエンベロープ蛋 白質またはそれからの免疫原性フラグメントをコードする請求項1記載の組換え アライグマポックスウイルス。 3.該内部遺伝子が、FIVエンベロープ蛋白質のアミノ酸1-735をコー ドする請求項2記載の組換えアライグマポックスウイルス。 4.ネコ免疫不全症ウイルス(FIV)のエンベロープ蛋白質またはそれからの 免疫原性フラグメントをコードするDNA配列を含む少なくとも1個の内部遺伝 子を有する組換えアライグマポックスウイルス、および 医薬上許容される担体または希釈剤を含んでなるワクチン。 5.さらに、医薬上許容されるアジュバントを含んでなる請求項4記載のワク チン。 6.該内部遺伝子が、図3記載のアミノ酸配列を有するFIVエンベロープ蛋 白質またはそれからの免疫原性フラグメントをコードする請求項6記載のワクチ ン。 7.該内部遺伝子が、FIVエンベロープ蛋白質のアミノ酸1-735をコー ドする請求項4記載のワクチン。 8.さらに、ネコ白血病ウイルス、ネコ汎白血球減少症ウイルス、ネコ鼻気管 炎ウイルス、ネコカリチウイルス、ネコ伝染性腹膜炎ウイルス、ネコヘルペスウ イルス、ネコ腸コロナウイルス、およびそれらの混合物よりなる群から選択され るウイルス由来の免疫原を含んでなる請求項4記載のワクチン。 9.さらに、不活化または弱毒化したネコ Chlamydia psittaci、Microsporum canis、またはそれらの混合物を含んでなる請求項4記載のワクチン。 10.ネコ免疫不全症ウイルス(FIV)のgag蛋白質またはそれからの免疫 原性フラグメントをコードするDNA配列を含む少なくとも1個の内部遺伝子を 有する組換えアライグマポックスウイルス。 11.該内部遺伝子が、図5記載のアミノ酸配列を有するFIVgag蛋白質 またはそれからの免疫原性フラグメントをコードする請求項10記載の組換えア ライグマポックスウイルス。 12.ネコ免疫不全症ウイルス(FIV)のgag蛋白質またはそれからの免疫 原性フラグメントをコードするDNA配列を含む少なくとも1個の内部遺伝子を 有する組換えアライグマポックスウイルス、および 医薬上許容される担体または希釈剤を含んでなるワクチン。 13.さらに、医薬上許容されるアジュバントを含んでなる請求項12記載の ワクチン。 14.該内部遺伝子が、図5記載のアミノ酸配列を有するFIVgag蛋白質 またはそれからの免疫原性フラグメントをコードする請求項12記載のワクチン 。 15.さらに、ネコ白血病ウイルス、ネコ汎白血球減少症ウイルス、ネコ鼻気 管炎ウイルス、ネコカリチウイルス、ネコ伝染性腹膜炎ウイルス、ネコヘルペス ウイルス、ネコ腸コロナウイルス、およびそれらの混合物よりなる群から選択さ れるウイルス由来の免疫原を含んでなる請求項12記載のワクチン。 16.さらに、不活化または弱毒化したネコChlamydia psittaci、Microsporu m canis、またはそれらの混合物を含んでなる請求項12記載のワクチン。 17.ネコ免疫不全症ウイルス(FIV)のgag、エンベロープ蛋白質、およ びそれらからの免疫原性フラグメントよりなる群から選択されるメンバーをコー ドするDNA配列を含む少なくとも1個の内部遺伝子を有する第一組換えアライ グマポックスウイルス; ネコ免疫不全症ウイルス(FIV)のgag、エンベロープ蛋白質、およびそれ らからの免疫原性フラグメントよりなる群から選択されるメンバーをコードする DNA配列を含む少なくとも1個の内部遺伝子を有する第二組換えアライグマポ ックスウイルス;および 医薬上許容される担体および希釈剤 を含んでなるワクチン。 18.さらに、医薬上許容されるアジュバントを含んでなる請求項17記載の ワクチン。 19.ネコ免疫不全症ウイルス(FIV)のエンベロープ蛋白質またはそれから の免疫原性フラグメントをコードするDNA配列を含む少なくとも1個の内部遺 伝子を有する組換えアライグマポックスウイルスを含むワクチンを、かかる治療 を要するネコに投与することを特徴とする、ネコ免疫不全症ウイルス(FIV)に よって引き起こされた疾病を予防または軽減するための方法。 20.該内部遺伝子が、図3記載のアミノ酸配列を有するFIVエンベロープ 蛋白質またはそれからの免疫原性フラグメントをコードする請求項19記載の方 法。 21.ネコ免疫不全症ウイルス(FIV)のgag蛋白質またはそれからの免疫 原性フラグメントをコードするDNA配列を含む少なくとも1個の内部遺伝子を 有する組換えアライグマポックスウイルスを含むワクチンをかかる治療を要する ネコに投与することを特徴とする、ネコ免疫不全症ウイルス(FIV)によって引 き起こされた疾病を予防または軽減するための方法。 22.該内部遺伝子が、図5記載のアミノ酸配列を有するFIVgag蛋白質 またはそれからの免疫原性フラグメントをコードする請求項21記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/482,090 US5820869A (en) | 1995-06-07 | 1995-06-07 | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US08/482,090 | 1995-06-07 | ||
PCT/US1996/008508 WO1996040268A1 (en) | 1995-06-07 | 1996-06-03 | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11506614A true JPH11506614A (ja) | 1999-06-15 |
JP4052667B2 JP4052667B2 (ja) | 2008-02-27 |
Family
ID=23914612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50108697A Expired - Fee Related JP4052667B2 (ja) | 1995-06-07 | 1996-06-03 | 組換えアライグマポックスウイルス、およびネコ免疫不全症ウイルス感染症に対する有効なワクチンとしてのその使用 |
Country Status (17)
Country | Link |
---|---|
US (2) | US5820869A (ja) |
EP (2) | EP1374910B1 (ja) |
JP (1) | JP4052667B2 (ja) |
AR (2) | AR003425A1 (ja) |
AT (2) | ATE361762T1 (ja) |
AU (1) | AU699794B2 (ja) |
BR (1) | BR9609089A (ja) |
CA (1) | CA2224257C (ja) |
CO (1) | CO4750842A1 (ja) |
DE (2) | DE69637080T2 (ja) |
DK (1) | DK0831921T3 (ja) |
ES (1) | ES2213178T3 (ja) |
HK (2) | HK1008982A1 (ja) |
PT (1) | PT831921E (ja) |
SI (1) | SI0831921T1 (ja) |
WO (1) | WO1996040268A1 (ja) |
ZA (1) | ZA964694B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000002707A (ja) * | 1998-05-15 | 2000-01-07 | Idexx Lab Inc | Env/gagポリペプチドマ―カ―を使用するネコ免疫不全ウイルス感染の診断 |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087234B1 (en) | 1991-07-09 | 2006-08-08 | Cornell Research Foundation, Inc. | Recombinant multivalent viral vaccine |
US6254872B1 (en) * | 1995-08-25 | 2001-07-03 | University Of Florida | Multi-subtype FIV vaccines |
FR2772047B1 (fr) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
US6106841A (en) * | 1998-02-04 | 2000-08-22 | Heska Corporation | Delivery method for recombinant raccoon poxvirus |
FR2775601B1 (fr) * | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
FR2776928B1 (fr) * | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
US7279168B2 (en) | 1998-05-01 | 2007-10-09 | Texas A & M University System | Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof |
UA73718C2 (en) * | 1998-05-01 | 2005-09-15 | Schering Plough Ltd | Therapeutic vector expressing foreign dna, coding cat's cd80, cat's cd86, cat's cd28 or cat's ctla-4 and use thereof |
US6641816B1 (en) | 1998-06-26 | 2003-11-04 | Aventis Pasteur S.A. | Use of poxviruses as enhancer of specific immunity |
US6294176B1 (en) * | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
AU2799400A (en) * | 1999-01-29 | 2000-08-18 | Bavarian Nordic Research Institute A/S | Multiplex real-time pcr |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
EP1074625A3 (en) | 1999-06-14 | 2002-01-02 | Pfizer Products Inc. | DNA vaccine against feline immunodeficiency virus |
ES2170622B1 (es) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
MY129765A (en) * | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
US20030129161A1 (en) * | 2001-09-17 | 2003-07-10 | Hsien-Jue Chu | Interleukin-12 as a veterinary vaccine adjuvant |
WO2005026733A1 (en) * | 2003-09-11 | 2005-03-24 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2006011919A1 (en) * | 2004-06-30 | 2006-02-02 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
DE602004021724D1 (de) * | 2003-12-18 | 2009-08-06 | Idexx Lab Inc | Verfahren zum nachweis des felinen immunschwächevirus |
AU2005215629B2 (en) * | 2004-02-19 | 2009-01-29 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
US20060013827A1 (en) * | 2004-06-21 | 2006-01-19 | Dorothee Bienzle | Method of diagnosing FIV |
WO2006011920A1 (en) * | 2004-06-30 | 2006-02-02 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein |
WO2006011917A1 (en) * | 2004-06-30 | 2006-02-02 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
US7291338B2 (en) * | 2005-03-09 | 2007-11-06 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
AU2008260593A1 (en) * | 2007-05-30 | 2008-12-11 | Wyeth | Raccoon poxvirus expressing genes of feline antigens |
WO2011123781A1 (en) | 2010-04-02 | 2011-10-06 | Idexx Laboratories, Inc. | Detection of feline immunodeficiency virus |
UA114503C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
CA2925281C (en) | 2013-09-25 | 2022-05-03 | Zoetis Services Llc | Pcv2b divergent vaccine composition and methods of use |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
WO2015095811A2 (en) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
CA2986235A1 (en) | 2015-05-20 | 2016-11-24 | The Broad Institute, Inc. | Shared neoantigens |
TW202241500A (zh) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
US20190346442A1 (en) | 2016-04-18 | 2019-11-14 | The Broad Institute, Inc. | Improved hla epitope prediction |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2602478C3 (de) * | 1976-01-23 | 1980-10-09 | Behringwerke Ag, 3550 Marburg | Impfstoff gegen die Panleukopenie der Feliden |
ATE1070T1 (de) * | 1978-11-30 | 1982-06-15 | The Wellcome Foundation Limited | Abgeschwaechter stamm des bei feliden infektioese peritonitis verursachenden virus, verfahren zu seiner herstellung und ihn enthaltender impfstoff. |
US5266313A (en) * | 1987-02-03 | 1993-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms |
US5583112A (en) * | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
US5256767A (en) * | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
US5118602A (en) * | 1987-08-26 | 1992-06-02 | The Regents Of The University Of California | Feline T-lymphotropic lentivirus assay |
CA1341439C (en) * | 1987-08-26 | 2003-09-23 | Niels C. Pedersen | Feline t-lymphotropic lentivirus |
ATE208813T1 (de) * | 1988-02-16 | 2001-11-15 | Greatbatch Gen Aid Ltd | Modifizierte zellen mit resistenz gegen retroviralinfektionen |
US5324664A (en) * | 1988-08-08 | 1994-06-28 | The Upjohn Company | Herpes virus thymidien kinase-encoding DNA |
US5177014A (en) * | 1988-12-05 | 1993-01-05 | Idexx Laboratories, Inc. | Monoclonal antibodies to feline-T-lymphotropic lentivirus |
US5219725A (en) * | 1988-12-05 | 1993-06-15 | Idexx Laboratories Incorporated | Monoclonal antibodies to feline-t-lymphotropic lentivirus |
JP3058685B2 (ja) * | 1989-05-08 | 2000-07-04 | アイデックス ラボラトリーズ インコーポレーテッド | ネコt細胞リンパトロピック レンチウィルスのポリペプチド |
US5252348A (en) * | 1990-10-19 | 1993-10-12 | Univ. Of Florida Research Foundation, Inc. | Artificial viral envelopes |
US5242686A (en) * | 1990-11-07 | 1993-09-07 | American Home Products Corporation | Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same |
FR2669338A1 (fr) * | 1990-11-21 | 1992-05-22 | Centre Nat Rech Scient | Fragments peptidiques issus de la proteine externe du vif, anticorps antifragments, application de ceux-ci au diagnostic et/ou au traitement de l'immunodeficience feline. |
US6228608B1 (en) * | 1991-02-28 | 2001-05-08 | Aquila Biopharmaceuticals, Inc. | Recombinant FIV glycoprotein 160 and P24 gag protein |
AU2299892A (en) * | 1991-07-05 | 1993-02-11 | Regents Of The University Of California, The | Feline lymphoid cell lines capable of producing fiv |
US5413927A (en) * | 1991-09-03 | 1995-05-09 | North Carolina State University | Feline immunodeficiency virus isolate NCSU1Lb |
CA2122263A1 (en) * | 1991-10-28 | 1993-05-13 | Marc Girard | Induction of protection against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein |
ES2242954T3 (es) * | 1992-03-11 | 2005-11-16 | Powderject Vaccines, Inc. | Vacuna genetica para el virus de la inmunodeficiencia. |
ATE278018T1 (de) * | 1992-06-16 | 2004-10-15 | Centre Nat Rech Scient | Nukleotid- und peptidsequenzen des immunschwächevirus der katze, isolat wo und anwendungen der sequenzen in der diagnostik und zur verhinderung der infektion |
PT576092E (pt) * | 1992-06-26 | 2003-02-28 | Akzo Nobel Nv | Vacina de virus de herpes felino recombinante |
GB9215232D0 (en) * | 1992-07-17 | 1992-09-02 | Pitman Moore Inc | Vaccines |
GB9215233D0 (en) * | 1992-07-17 | 1992-09-02 | Pitman Moore Inc | Vaccines |
WO1994006921A1 (en) * | 1992-09-21 | 1994-03-31 | Viagene, Inc. | Recombinant retroviral vector against felv and/or fiv |
GB9219936D0 (en) * | 1992-09-21 | 1992-11-04 | Pitman Moore Inc | Vaccines |
EP0670901A1 (en) * | 1993-03-11 | 1995-09-13 | Akzo Nobel N.V. | Polypeptide fragment capable of inducing neutralising antibodies against feline immuno-deficiency virus |
TW377373B (en) * | 1993-09-22 | 1999-12-21 | Wyeth Corp | Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease |
-
1995
- 1995-06-07 US US08/482,090 patent/US5820869A/en not_active Expired - Lifetime
-
1996
- 1996-06-03 CA CA002224257A patent/CA2224257C/en not_active Expired - Fee Related
- 1996-06-03 DE DE69637080T patent/DE69637080T2/de not_active Expired - Fee Related
- 1996-06-03 DK DK96917038T patent/DK0831921T3/da active
- 1996-06-03 BR BR9609089A patent/BR9609089A/pt not_active Application Discontinuation
- 1996-06-03 PT PT96917038T patent/PT831921E/pt unknown
- 1996-06-03 DE DE69631246T patent/DE69631246T2/de not_active Expired - Fee Related
- 1996-06-03 AT AT03013934T patent/ATE361762T1/de not_active IP Right Cessation
- 1996-06-03 ES ES96917038T patent/ES2213178T3/es not_active Expired - Lifetime
- 1996-06-03 SI SI9630663T patent/SI0831921T1/xx unknown
- 1996-06-03 WO PCT/US1996/008508 patent/WO1996040268A1/en active IP Right Grant
- 1996-06-03 AT AT96917038T patent/ATE257015T1/de not_active IP Right Cessation
- 1996-06-03 AU AU59731/96A patent/AU699794B2/en not_active Ceased
- 1996-06-03 EP EP03013934A patent/EP1374910B1/en not_active Expired - Lifetime
- 1996-06-03 EP EP96917038A patent/EP0831921B1/en not_active Expired - Lifetime
- 1996-06-03 JP JP50108697A patent/JP4052667B2/ja not_active Expired - Fee Related
- 1996-06-05 ZA ZA9604694A patent/ZA964694B/xx unknown
- 1996-06-05 AR ARP960102963A patent/AR003425A1/es unknown
- 1996-06-06 CO CO96029449A patent/CO4750842A1/es unknown
-
1998
- 1998-01-15 US US09/007,383 patent/US5989562A/en not_active Expired - Lifetime
- 1998-08-07 HK HK98109771A patent/HK1008982A1/xx not_active IP Right Cessation
-
2001
- 2001-03-27 AR ARP010101441A patent/AR042378A2/es active IP Right Grant
-
2004
- 2004-05-28 HK HK04103836A patent/HK1060847A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000002707A (ja) * | 1998-05-15 | 2000-01-07 | Idexx Lab Inc | Env/gagポリペプチドマ―カ―を使用するネコ免疫不全ウイルス感染の診断 |
Also Published As
Publication number | Publication date |
---|---|
US5989562A (en) | 1999-11-23 |
EP0831921B1 (en) | 2004-01-02 |
CA2224257A1 (en) | 1996-12-19 |
HK1060847A1 (en) | 2004-08-27 |
DE69631246T2 (de) | 2004-11-25 |
BR9609089A (pt) | 1999-02-02 |
HK1008982A1 (en) | 1999-05-21 |
DE69637080T2 (de) | 2008-01-10 |
AU5973196A (en) | 1996-12-30 |
ATE361762T1 (de) | 2007-06-15 |
PT831921E (pt) | 2004-05-31 |
EP0831921A1 (en) | 1998-04-01 |
ZA964694B (en) | 1997-12-05 |
CO4750842A1 (es) | 1999-03-31 |
ES2213178T3 (es) | 2004-08-16 |
ATE257015T1 (de) | 2004-01-15 |
CA2224257C (en) | 2005-08-16 |
AU699794B2 (en) | 1998-12-17 |
EP1374910A1 (en) | 2004-01-02 |
WO1996040268A1 (en) | 1996-12-19 |
DE69631246D1 (de) | 2004-02-05 |
US5820869A (en) | 1998-10-13 |
DE69637080D1 (de) | 2007-06-21 |
DK0831921T3 (da) | 2004-04-26 |
SI0831921T1 (en) | 2004-06-30 |
EP1374910B1 (en) | 2007-05-09 |
AR042378A2 (es) | 2005-06-22 |
AR003425A1 (es) | 1998-08-05 |
JP4052667B2 (ja) | 2008-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4052667B2 (ja) | 組換えアライグマポックスウイルス、およびネコ免疫不全症ウイルス感染症に対する有効なワクチンとしてのその使用 | |
US7255862B1 (en) | ALVAC/FIV constructs | |
US5849303A (en) | Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection | |
EP0652967B1 (en) | Self-assembling replication defective hybrid virus particles | |
JPH08500969A (ja) | 七面鳥の組換えヘルペスウイルス及びそれらの使用 | |
Kondo et al. | Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent | |
EP0652287B1 (en) | Poxviral vectors and their use as a vaccine against feline infectious peritonitis virus disease | |
US5651972A (en) | Use of recombinant swine poxvirus as a live vaccine vector | |
JPH11507515A (ja) | 遺伝的に改変したネコ免疫不全症ウイルス、およびネコ免疫不全症ウイルス感染症に対する有効なワクチンとしてのその使用 | |
CA2237807C (en) | Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them | |
US5783192A (en) | Recombinant feline herpesvirus vaccine | |
US6241989B1 (en) | Recombinant multivalent viral vaccine | |
US6458362B1 (en) | Recombinant VP2 parvoviral pseudo-particles encoding CTL or T-helper cell epitopes | |
US6521236B1 (en) | Vector vaccine of recombinant feline herpesvirus | |
CA2127700C (en) | Marek's disease virus recombinant poxvirus vaccine | |
JPH06510910A (ja) | ネコ白血病ウイルスワクチン | |
US7087234B1 (en) | Recombinant multivalent viral vaccine | |
US20080299149A1 (en) | Raccoon Poxvirus Expressing Genes of Feline Antigens | |
JP2002501369A (ja) | Fivワクチン | |
AU769221B2 (en) | Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them | |
Rutkowska | The development of vaccine delivery systems based on presenting peptides on the surface of core protein VP7 of African horse sickness virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060606 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060825 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061206 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070320 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070614 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070730 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070920 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071113 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071204 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101214 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |